This week's valuation screen pulled from the FMP DCF Valuation API surfaced a familiar but increasingly persistent signal: modeled cash flows and market pricing are drifting apart across multiple sectors at once. The dispersion isn't isolated—it's showing up in software, healthcare, consumer staples, and industrial inputs, suggesting a broader mismatch between embedded expectations and current capital positioning.
In this note, we break down five names where that gap is most pronounced, using the same API workflow to track how far price has moved from modeled intrinsic value—and why those spreads are starting to matter now.
Key Takeaways
- Cross-sector consistency: Software, healthcare, agriculture, and industrial names are all showing similar DCF-to-price dislocations, pointing to a broader shift in how risk and duration are being priced.
- Valuation gaps reflect assumption drift: The spread is less about mispricing in isolation and more about differences in how future cash flows are being discounted versus modeled.
- Context requires multiple datasets: Pairing DCF outputs with income statements, analyst targets, and segment data helps explain why these gaps exist, not just that they exist.
- Signal strength comes from repetition: When the same pattern appears across unrelated sectors, it becomes a more reliable framework for tracking how expectations evolve over time.
Five Names Flagged by This Week's Valuation Scan
Open Text Corporation (OTEX)
DCF Value: $144.47 — Market Price: $23.2 → Upside Potential: +522.7%
The scale of the spread here stands out immediately. A modeled value of $144.47 against a $23.20 market price implies a +522.7% gap — the widest in this week's screen. That magnitude typically doesn't emerge from a single variable; it reflects a compounding effect of assumptions around cash flow durability, margin structure, and cost of capital diverging materially from how the market is currently discounting the business.
In OpenText's case, the signal sits at the intersection of legacy software repositioning and balance sheet scrutiny following recent acquisitions. The company has been integrating large-scale assets while managing leverage, which tends to compress multiples even when cash flow remains intact. Looking deeper into income statement trends—particularly operating margin trajectory and amortization load—helps clarify whether the model's higher valuation is anchored in normalized profitability that the market is not yet pricing consistently. The spread itself doesn't resolve the discrepancy, but it isolates where assumptions are most misaligned.
Jazz Pharmaceuticals plc (JAZZ)
DCF Value: $578.42 — Market Price: $202.72 → Upside Potential: +185.3%
Jazz Pharmaceuticals shows a +185.3% valuation gap, a level that often signals tension between near-term earnings visibility and longer-duration cash flow expectations. Biopharma names frequently exhibit this pattern when revenue concentration or pipeline transition risk influences how aggressively future cash flows are discounted.
Here, the divergence appears tied to the company's evolving product mix and lifecycle dynamics. Market pricing tends to reflect sensitivity to patent cliffs and clinical execution, while DCF frameworks often extend value further into the pipeline horizon. Reviewing product-level revenue breakdowns within segment reporting, alongside analyst estimate revisions, provides context on whether forward assumptions embedded in the model remain aligned with consensus expectations. The spread highlights that the disagreement is less about current performance and more about how future contributions are being weighted.
Cal-Maine Foods, Inc. (CALM)
DCF Value: $144.78 — Market Price: $76.25 → Upside Potential: +89.9%
Cal-Maine's +89.9% gap reflects a different type of signal—one shaped by commodity exposure and earnings cyclicality rather than structural uncertainty. As a producer operating within the agricultural supply chain, its cash flows are heavily influenced by input costs, pricing cycles, and external shocks such as feed inflation or disease-related supply disruptions.
The valuation disconnect here often emerges when models smooth earnings across cycles, while the market anchors more heavily to recent peak or trough conditions. In periods following elevated egg prices, for example, normalization expectations can weigh on valuation even if longer-term averages remain supportive. Examining historical revenue and margin volatility through income statements, as well as commodity price datasets, helps determine whether the modeled value reflects mid-cycle assumptions that differ from the market's current reference point. The signal is less about mispricing in isolation and more about where in the cycle each framework is anchored.
Merck & Co., Inc. (MRK)
DCF Value: $216.40 — Market Price: $112.16 → Upside Potential: +92.9%
Merck's +92.9% spread appears against the backdrop of one of the more closely followed large-cap pharmaceutical franchises. At this scale, valuation gaps tend to center on a narrow set of drivers—primarily the durability of key assets and the timing of revenue transitions rather than broad uncertainty about the business model.
The company's reliance on flagship therapies introduces a clear focal point for both valuation models and market pricing. DCF frameworks may extend the contribution of leading products further into the future, while the market typically discounts the impact of eventual loss of exclusivity earlier. Reviewing segment-level revenue concentration and pipeline development timelines, alongside consensus target price distributions, provides a clearer view of how each side is weighting that transition. The gap highlights a difference in timing assumptions rather than a disagreement on current fundamentals.
Darling Ingredients Inc. (DAR)
DCF Value: $89.67 — Market Price: $63.77 → Upside Potential: +40.6%
Darling Ingredients presents the narrowest spread in this group at +40.6%, but still enough to surface within the screen. The company operates within renewable fuels and waste-to-value conversion—areas that have seen shifting sentiment tied to policy frameworks, energy pricing, and capital intensity considerations.
The valuation gap here appears linked to how future cash flows from sustainability-driven segments are being discounted. Models often incorporate longer-term demand assumptions tied to biofuel adoption and regulatory support, while market pricing can fluctuate with changes in subsidy structures or feedstock economics. Analyzing cash flow statements for capex intensity and segment-level EBITDA contributions, alongside policy-related disclosures, helps clarify whether the modeled value reflects conditions that the market is currently treating more conservatively. The spread signals a divergence in how durable those tailwinds are perceived to be.
Reading a Common Signal Across Unrelated Sectors
What links these five names isn't sector exposure or business model—it's the consistency of the valuation spread itself. Software, biopharma, agriculture, large-cap pharma, and industrial processing are all showing the same structural signal: modeled cash flow assumptions are not lining up with how the market is currently discounting those cash flows. That kind of cross-sector alignment tends to point less to idiosyncratic mispricing and more to a broader shift in how risk, duration, or earnings visibility is being priced.
A pattern like this often emerges when the market compresses uncertainty into the discount rate rather than adjusting individual company narratives. In practice, that shows up as lower multiples applied across different industries, even when underlying cash flow profiles remain intact. The DCF outputs, by contrast, tend to hold those assumptions more stable—particularly around normalized margins or long-term growth—creating a widening gap when sentiment shifts faster than fundamentals. The result is not necessarily “undervaluation” in a directional sense, but a measurable divergence in how forward expectations are being framed.
This is where combining multiple datasets becomes critical. A DCF snapshot highlights the gap, but it doesn't explain it on its own. When those spreads are layered against income statement trends from financial endpoints, shifts in operating leverage or margin compression become more visible. Adding analyst target data helps determine whether the broader sell-side is converging with the model or reinforcing the market's stance. In cases like Jazz or Merck, pipeline and segment-level revenue data provide context on how much of the valuation depends on concentrated future drivers. For cyclicals like Cal-Maine or Darling, pairing DCF outputs with historical commodity-linked revenue volatility or cash flow sensitivity to input costs can clarify whether the model is anchored to mid-cycle assumptions while the market is pricing nearer-term conditions—an approach that reflects how integrated datasets available through Financial Modeling Prep are increasingly used to reconcile valuation signals with underlying fundamentals.
Taken together, the signal here is less about any single company and more about alignment—or lack of it—between different layers of the data stack. When DCF values, reported fundamentals, and external expectations (like analyst targets or revisions) begin to diverge simultaneously across sectors, it creates a more structured way to monitor where assumptions are drifting. That drift, rather than the absolute level of any one metric, is what tends to carry the most informational value over time.
Turning DCF Snapshots Into a Live, Repeatable Signal
A single DCF output can highlight a pricing gap, but on its own it's just a snapshot. Market prices update continuously, while model inputs—growth rates, margins, discount assumptions—shift as new data comes in. To make the signal usable, the focus needs to move from one-off checks to consistent data capture. That means running the same extraction on a schedule, storing each pull, and observing how valuation spreads change over time rather than treating them as isolated readings.
Before starting the workflow, confirm that your API key is properly configured and accessible in your environment.
Step 1. Query the DCF Valuation API
The workflow starts with the DCF Valuation API, which serves as the foundation for the entire process. This endpoint returns both the modeled intrinsic value and the current market price in one response, removing the need to reconcile multiple data sources before analysis begins. Having valuation and price captured together ensures consistency and reduces the risk of timing mismatches that can distort comparisons.
Sample response
[
{
"symbol": "AAPL",
"date": "2025-02-04",
"dcf": 147.27,
"Stock Price": 231.80
}
]
Step 2. Compute the Upside
With both fields in hand, the next step is to normalize the gap. Converting the difference between DCF and market price into a percentage allows the results to be compared across names with very different share prices:
Upside % = (DCF - Stock Price) / Stock Price × 100
In the example above, the calculation produces roughly -36%, indicating the stock is trading above the modeled intrinsic value. Positive figures flag the opposite condition—where price sits below DCF—which is the core signal this screen is designed to capture.
Step 3. Scale It into a Screening Loop
The workflow becomes materially more useful once this logic is applied at scale. Running the DCF endpoint across a defined universe, calculating the percentage spread for each symbol, storing the results, and ranking them by upside converts a static check into a living screen. When automated on a recurring cadence, the process continuously surfaces where price and intrinsic value are drifting further apart or beginning to converge, making it easier to monitor valuation pressure as market conditions shift.
Stabilizing the Workflow Before Scaling It
The starting point isn't scale—it's reliability. A DCF screen only has value if it produces consistent outputs under the same conditions, which means the initial focus is running it against a small, controlled universe and pressure-testing each step. At this stage, the FMP Basic plan is typically sufficient. The goal is to confirm that the DCF values reconcile cleanly, the spread calculations hold up, and rankings adjust as new data flows in. Once those mechanics are stable, the process shifts from a one-off check to something you can rely on.
Scaling from there is less about changing the approach and more about extending its reach. The FMP Starter plan applies the same framework across a broader slice of the market, with added historical depth. Nothing about the methodology changes—the same endpoint, the same normalization, the same ranking logic. The only difference is coverage. That continuity matters, because it allows the signal to expand without introducing inconsistencies.
For workflows that need to run more frequently or across multiple regions, the FMP Premium plan addresses throughput. Higher request limits and access to additional exchanges make it possible to keep the process running on a steady cadence, whether tied to earnings cycles or ongoing estimate revisions. At that point, the screen becomes part of the regular workflow—updating alongside the market rather than reacting to it.
From Desk-Level Tooling to Shared Research Infrastructure
Workflows that consistently surface useful signals don't stay isolated for long. Once a valuation screen starts feeding into team discussions—whether in sector reviews, portfolio construction, or risk oversight—the gaps between individual implementations become harder to ignore. Slight differences in formulas, timing of data pulls, or even ticker coverage introduce inconsistencies that complicate comparisons. The math may be aligned in principle, but the outputs begin to diverge in practice.
That inflection point is where individual tooling gives way to institutional thinking. Analysts who have spent time refining the workflow are typically the ones pushing for alignment—standardizing inputs, locking down calculation logic, and moving the process out of personal spreadsheets into shared environments. The shift is less about control and more about coherence: synchronized updates, uniform assumptions, and a common reference point across teams. Once centralized, the workflow becomes easier to interrogate, extend, and trust.
As adoption broadens across desks and regions, structure becomes necessary. Shared dashboards replace isolated files, historical outputs are preserved for auditability, and access controls ensure that updates don't introduce conflicting versions of the same model. At that stage, the focus shifts from building the screen to maintaining its integrity—ensuring that what's being discussed in one part of the organization reflects the same underlying data and logic elsewhere.
For workflows that have already proven themselves at the desk level, this transition often leads to a more formal setup. An institutional framework such as the Enterprise Plan provides a way to support that shift—offering controlled data access, consistent delivery, and the infrastructure needed to keep the methodology aligned as usage scales. What begins as an analyst-driven screen gradually becomes embedded as part of the firm's shared research system.
Using Valuation Gaps to Frame What Comes Next
Valuation spreads like these are less about single-point conclusions and more about tracking how assumptions evolve against price. Using the FMP DCF Valuation API as a consistent reference point, the signal becomes a way to monitor where expectations are stabilizing—or continuing to drift—as new data comes in.
Expand your watchlist with our previous deep dive: Weekly Signals Desk | Price-Target Gaps Identified via the FMP API (April 20-24)
Disclosure: Signals Desk content is provided for informational and analytical purposes only and does not constitute investment advice or trade recommendations. The analysis reflects interpretation of market data and publicly disclosed or third-party information, including data accessed via Financial Modeling Prep APIs, at the time of publication. Signals discussed are probabilistic, can be wrong, and may change as market conditions and consensus data evolve. This content should be considered alongside broader research, individual objectives, and risk assessment.
